Cinnarizine

Cinnarizine

Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy category	C (US)
Routes of administration	Oral
ATC code	N07CA02 (WHO)
Pharmacokinetic data
Elimination half-life	3..4h
Identifiers
IUPAC name 1-benzhydryl-4-cinnamyl-piperazine
CAS Number	298-57-7 Y
PubChem CID	1547484
DrugBank	DB00568 Y
ChemSpider	1264793 Y
UNII	3DI2E1X18L
KEGG	D01295 Y
ChEBI	CHEBI:31403 Y
ChEMBL	ChEMBL43064 Y
CompTox Dashboard (EPA)	DTXSID80859311 DTXSID3022821, DTXSID80859311
ECHA InfoCard	100.005.514
Chemical and physical data
Formula	C26H28N2
Molar mass	368.514 g/mol g·mol−1
3D model (JSmol)	Interactive image
SMILES c1c(cccc1)C(c2ccccc2)N3CCN(CC3)C\C=C\c4ccccc4
InChI InChI=1S/C26H28N2/c1-4-11-23(12-5-1)13-10-18-27-19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-17,26H,18-22H2/b13-10+ Y Key:DERZBLKQOCDDDZ-JLHYYAGUSA-N Y
(verify)

Cinnarizine (Stugeron, Stunarone, R5) is an antihistamine which is mainly used for the control of nausea and vomiting due to motion sickness. Cinnarizine was first synthesized by Janssen Pharmaceutica in 1955. It is not available in the United States or Canada. It is manufactured and marketed in Bangladesh under the trade name Suzaron by Rephco Pharmaceuticals Limited.

It acts by interfering with the signal transmission between vestibular apparatus of the inner ear and the vomiting centre of the hypothalamus. The disparity of signal processing between inner ear motion receptors and the visual senses is abolished, so that the confusion of brain whether the individual is moving or standing is reduced. Vomiting in motion sickness is actually a physiological compensatory mechanism of the brain to keep the individual from moving so that it can adjust to the signal perception.

Cinnarizine could be also viewed as a nootropic drug because of its vasorelaxating abilities (due to calcium channel blockage), which happen mostly in brain. It is also effectively combined with other nootropics, primarily Piracetam; in such combination each drug potentiate the other in boosting brain oxygen supply.

While this may be true, cinnarizine is also known to cause acute and chronic parkinsonism probably due to its affinity for D2 receptors, which strongly countersuggests its actual usefulness for improving neurohealth.

Cinnarizine can be used in scuba divers without an increased risk of central nervous system oxygen toxicity.

Cinnarizine can cause drowsiness and blurred vision. It is important that users make sure their reactions are normal before driving, operating machinery, or doing any other jobs which could be dangerous if they are not fully alert or able to see well.

References

• Barrett RJ, Zolov B (1960). "A clinical evaluation of cinnarizine (Mitronal) in various allergic disorders". J Maine Med Assoc. 51: 454–7. PMID 13687289. {{cite journal}}: Unknown parameter |month= ignored (help)
• Towse G (1980). "Cinnarizine--a labyrinthine sedative". J Laryngol Otol. 94 (9): 1009–15. doi:10.1017/S0022215100089787. PMID 7000939. {{cite journal}}: Unknown parameter |month= ignored (help)